Why Lenacapavir is Important … and Expensive
Lenacapavir has the potential to transform HIV care and prevention, but only if access is broadened, according to Jose Abrigo, Esq., HIV Project Director of the Lambda Legal Defense and Education Fund.
Injectable lenacapavir, the investigational twice-yearly antiretroviral, has created quite the buzz this year, reporting an almost 100% success rate at preventing HIV in clinical trials, when compared to placebo. However, this success comes with a price, up to $44,819 per person per year, according to an article published in the Journal of Antimicrobial Chemotherapy.
This price tag is expected to cause access issues, according to Jose Abrigo, Esq., HIV Project Director of the Lambda Legal Defense and Education Fund.
“Insurers are disincentivized to cover really expensive drugs,” Abrigo said in an interview with Managed Healthcare Executive. “Because insurance companies don't want to spend money, if there is a viable alternative, they will deny it and say, ‘take the others.’ That analysis isn't fully informed sometimes because sometimes the medical records submitted to them are incomplete, doctors don't know how to word the request and just the default for most insurers to deny.”
Lenacapavir is already FDA-approved for patients with drug resistant HIV, under the brand name Sunlenca.
Trump Budget Axes CDC HIV Prevention, Shifts Care, Experts Warn of Risks
June 10th 2025Although some HIV programs will remain, the proposed cuts in the fiscal year 2026 budget are too severe and will hinder HIV care and research in the United States, according to Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C.
Read More
Most HIV Patients Trust Their Providers But Don’t Always Feel Heard, Survey Says
May 27th 2025Almost half (48%) of HIV patients sometimes feel unheard by their healthcare providers, which highlights a need for increased disease awareness, according to the early results of a new ViiV Healthcare survey.
Read More
HIV Antiretroviral Reduced Alzheimer’s Risk Continuously, Study Shows
May 8th 2025Previously used to treat HIV and Hepatitis B, nucleoside reverse transcriptase inhibitors (NRTIs) reduced the risk of Alzheimer’s disease by an average of 9% every year, according to new research published in Alzheimer’s and Dementia.
Read More
